# GLP-1 REceptor Agonists and Real World EvIdeNce

> **NCT03959865** · — · UNKNOWN · sponsor: **University of Padova** · enrollment: 6000 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Long-acting GLP-1RA
- **DRUG:** Short-acting GLP-1RA
- **DRUG:** Human-based GLP-1RA
- **DRUG:** Exendin-based GLP-1RA
- **DRUG:** Fixed ratio BI/GLP-1RA combination
- **DRUG:** Flexible BI/GLP-1RA combination

## Key facts

- **NCT ID:** NCT03959865
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-19
- **Primary completion:** 2019-02-11
- **Final completion:** 2019-05-31
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959865, "GLP-1 REceptor Agonists and Real World EvIdeNce". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03959865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*